AMO Pharma Announces Additional Private Equity Investment Following Progress in Phase 3 Study in Congenital Myotonic Dystrophy

Current investors in AMO Pharmaceutical Industry Increases Funding as Company Passes Two-Thirds Enrollment Milestone in Pivotal REACH-CDM Clinical Trial

LONDON, May 10, 2022 /PRNewswire/ — AMO Pharma Limited (“AMO Pharma”), a privately held biopharmaceutical company specializing in rare childhood neurogenetic disorders with limited or no treatment options, today announced that current investors have made additional investments in the company in response to progress in AMO Pharma’s potentially pivotal REACH-CDM study, a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of AMO-02 (tideglusib) for the treatment of congenital myotonic dystrophy (CDM1).

“With recent announcements regarding our progress in recruiting patients and expanding clinical trial sites in the REACH-CDM trial, we have seen new levels of momentum and interest in this research effort without precedent and history from industry partners, families, clinicians and investors,” said Ibrahim Mahmoud, AMO Pharmaceutical CEO. “We are very pleased that this interest is shared by current investors in AMO Pharmacy.”

In December 2021, AMO Pharma announced the activation of additional clinical trial sites in Australia and New Zealand for the REACH-CDM trial and confirmed that more than two-thirds of the patients had been enrolled in the trial. The REACH-CDM trial will enroll a total of 56 patients. At the end of the trial, patients will have the option to cross over into REACH-CDM X, a 52-week open-label study designed to assess the long-term safety and efficacy of AMO-02.

“With REACH-CDM, we strive to bring a treatment option and the possibility of better health and significantly improved quality of life to patients living with the most severe and earliest form of dystrophy. myotonic,” said Dr. Joseph Horriganchief physician at AMO Pharmacy. “We remain committed to moving this development effort forward as quickly as possible and are very encouraged by the new levels of support and interest we are seeing from our investors as well as potential industry partners around the world. “

On AMO-02

AMO-02 (tideglusib) is being developed for the treatment of congenital myotonic dystrophy and has the potential to be used in adult myotonic dystrophy, supplemental CNS, neuromuscular and other orphan indications. AM0-02 is an investigational clinical-stage drug for the treatment of the severe form of congenital myotonic dystrophy known as CDM1 or Steinert’s disease. AMO-02 has a dual mechanism disrupting pathogenic RNA repeat in CDM1 and inhibiting excessive levels of GSK3β kinase.

On AMO Pharmacy

AMO Pharma is a biopharmaceutical company focused on identifying and advancing promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare and severe neurogenetic disorders of childhood with limited or no treatment options. In addition to developing AMO-02 for congenital myotonic dystrophy, the company is also progressing AMO-01 as a treatment for the clinical stage of Phelan-McDermid syndrome and AMO-04 as a potential clinically ready drug for Rett syndrome and related disorders. AMO-02, AMO-01 and AMO-04 are investigational drugs that have not yet been approved for the treatment of patients anywhere in the world. For more information, please visit the AMO Pharmacy website at http://www.amo-pharma.com/.

Media contact:
Bill Berry
Berry & Company Public Relations
[email protected]
212-253-8881

Quote

Show original content:https://www.prnewswire.com/news-releases/amo-pharma-announces-additional-private-equity-investment-following-progress-in-phase-3-study-in-congenital-myotonic-dystrophy-301543387. html

THE SOURCE AMO Pharma Limited

Comments are closed.